Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 1.39 Billion |
| Market Size (2030) | USD 1.91 Billion |
| Growth Rate (2025 - 2030) | 6.58% CAGR |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
France Diabetes Devices Market Analysis by Mordor Intelligence
The France diabetes devices market reached USD 1.39 billion in 2025 and is projected to attain USD 1.91 billion by 2030, equating to a 6.58% CAGR and pointing to steady mid-single-digit expansion over the next five years. This momentum reflects the world-first decision by France to reimburse continuous glucose monitoring (CGM) for every insulin user, including the 100,000 people with Type 2 diabetes who received coverage for Dexcom ONE in mid-2024. Reimbursement removes cost barriers, so hospitals, diabetes specialty centers, and general practitioners prescribe sensors earlier in the care pathway. Public–private grants through France 2030 and the Important Project of Common European Interest (IPCEI) for Health reinforce domestic semiconductor capacity, cutting reliance on foreign sensors and stabilizing supply chains. Meanwhile, the “Mon Espace Santé” platform integrates real-time glucose data with electronic health records, streamlining teleconsultation, which rose six-fold among general practitioners between 2022 and 2024. Together, reimbursement, state funding, and digital connectivity give the France diabetes devices market a structural growth foundation that remains resilient to macro-economic swings.
Key Report Takeaways
By device type, monitoring devices captured 57.13% of the France diabetes devices market share in 2025; management devices are forecast to advance at a 3.10% CAGR to 2030.
By end user, hospitals and clinics held 48.27% revenue share in 2025, while home-care settings are expected to grow at a 3.00% CAGR through 2030.
By distribution channel, retail pharmacies accounted for 42.15% of the France diabetes devices market size in 2025; online sales will expand fastest at a 2.90% CAGR to 2030.
France Diabetes Devices Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising diabetes prevalence and aging population | +2.1 % | National; strongest in metropolitan areas | Long term (≥ 4 years) |
| Patient-centric home care & “Mon Espace Santé” telemonitoring | +1.8 % | National; early uptake in large cities | Medium term (2-4 years) |
| Nationwide expansion of reimbursement (LPPR listings) | +2.0 % | National; uniform across regions | Short term (≤ 2 years) |
| Ongoing technology improvements (factory-calibrated CGM, AI dosing) | +1.3 % | National; driven by innovation hubs | Medium term (2-4 years) |
| Government & EU funding (France 2030, IPCEI Health) for local R&D | +1.5 % | National; Grenoble & Toulouse clusters | Medium term (2-4 years) |
| Hybrid closed-loop & patch-pump solutions | +1.0 % | Nationwide; specialist centers first | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Rising diabetes prevalence & an aging population
Roughly 3.5 million French citizens live with diabetes, up from 2024 levels, and prevalence in men already ranges 3–5%. Incidence of Type 1 diabetes in children nearly tripled between the 1994-2003 and 2013-2022 periods. Higher case counts, longer lifespans, and more complex comorbidities boost durable demand for CGM, patch pumps, and data-driven care. As seniors adopt smartphones, CGM apps scale into older age brackets, widening revenue pools in the France diabetes devices market.
Patient-centric move to home care & telemonitoring
The state-run “Mon Espace Santé” portal lets patients push CGM data directly to physicians, enabling virtual dose adjustments and lowering travel burdens. Teleconsultations jumped six-fold since COVID-19, and remote prescribers can now bill for digital follow-ups under July 2023 reimbursement rules. Pharmacists, nurses, and dietitians receive real-time dashboards, creating a multidisciplinary continuum that raises adherence and reduces acute admissions. These changes stimulate sustained CGM reorder cycles, particularly in remote regions with fewer endocrinologists.
Government & EU funding strengthens local supply
France 2030 earmarks EUR 7.5 billion (USD 8.1 billion) for health innovation, including wafer-scale sensor fabrication lines in Auvergne-Rhône-Alpes; matching IPCEI grants cover equipment depreciation and cybersecurity R&D [1]OECD, “Assessment of Digital Medical Devices,” oecd.org. Start-ups gain technical support and accelerated pilot contracts. The PECAN fast-track process, launched in March 2024, allows qualified apps to skip full clinical trials once preliminary benefit is evident. Faster approval cycles pull forward revenue for connected pen caps and decision-support algorithms within the France diabetes devices market.
Hybrid closed-loop & patch-pump innovation
A 2024 multicenter study reported 76% time-in-range under closed-loop versus 61% for pump + CGM therapy, reflecting superior glycemic stability [2]Anne-Laure Borel, “Closed-Loop Insulin Therapy for People With Type 2 Diabetes,” diabetesjournals.org. National position papers now endorse AID in pediatric and adult cohorts, expanding device eligibility and reducing finger-stick frequency. Omnipod 5, now under evaluation in RADIANT, enables needle-free automated dosing and could unlock direct upgrades from multiple daily injections. Ecosystem convergence pushes the France diabetes devices market toward bundled sensor-pump-software solutions
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Stringent CEPS price caps and tendering processes compressing manufacturer margins and discouraging new entrants | -0.7% | National, affecting all market segments | Medium term (2-4 years) |
| Complex EU-MDR compliance and ANSM cybersecurity mandates prolonging certification timelines and raising regulatory costs | -0.5% | National, with EU-wide implications | Short term (≤ 2 years) |
| Shortage of diabetes-specialist nurses | -0.3% | National, more severe in rural areas | Medium term (2-4 years) |
| GLP-1 therapy reducing SMBG frequency | -0.2% | National, primarily affecting urban centers | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Stringent CEPS price caps compress margins
The Economic Committee for Health Products mandates pricing tied to clinical-benefit scores, limiting premium surcharges even for breakthrough devices. Hospitals must run competitive tenders that weigh price above features, squeezing suppliers. Manufacturers respond by shifting to subscription models where analytics and coaching carry extra value, but margin headroom remains thin across the France diabetes devices market.
Regulatory complexity prolongs certification
EU-MDR rules require detailed clinical and cybersecurity dossiers; notified bodies reported backlog-driven certificate delays averaging 13 months in 2024 [3]CORE-MD, “Report on Notified-Body Certificates,” core-md.eu. Companies incur added costs for penetration testing and encryption audits. Smaller start-ups often outsource compliance, raising upfront capital needs and potentially slowing their France diabetes devices market entry.
Segment Analysis
By Device Type: Monitoring Devices Dominate Amid Real-Time Data Shift
Monitoring devices generated 57.13% of revenue in 2025, underlining data’s central role in the France diabetes devices market. CGM overtakes self-monitoring blood glucose (SMBG) as reimbursement widens; Dexcom ONE coverage alone added 0.1 million Type 2 users. The France diabetes devices market size for monitoring devices equaled USD 0.79 billion in 2025 and is forecast to exceed USD 1.10 billion by 2030, implying a sensor unit CAGR ahead of total market due to falling average selling prices. Factory-calibrated Libre 3 sensors from Abbott provide 14-day wear without finger-stick confirmation, supporting rapid replacement cycles. Domestic fab capacity under France 2030 could lower BOM costs by 2027 and help new entrants attack price-sensitive segments.
Management devices—pens, pumps, and closed-loop systems—grow 3.10% annually from a smaller base. Updated 2024 guidelines extend AID to new cohorts, improving user confidence. The France diabetes devices market size for management devices reached USD 0.60 billion in 2025 and may touch USD 0.81 billion by 2030. Trials like RADIANT assess direct leaps from injections to full automation, potentially opening a pipeline of 450,000 pump-naïve adults. As sensors and pumps bundle, ecosystem lock-in intensifies, prompting third-party app developers to seek interoperable Bluetooth standards to safeguard user choice in the France diabetes devices market.
By End User: Home-Care Settings Gain Momentum
Hospitals and clinics controlled 48.27% revenue in 2025, reflecting concentration of specialist expertise and peri-operative glucose monitoring. Closed-loop initiation during inpatient stays sustains pump attachment rates, while CEPS procurement channels favor bulk purchases. Yet staff shortages, especially outside metro hubs, press facilities to off-load stable patients sooner, indirectly bolstering remote monitoring adoption across the France diabetes devices market.
Home-care settings record the quickest growth at 3.00% CAGR through 2030. Reimbursement introduced in July 2023 allows physicians to bill remote glucose reviews via the PPDP program. Seniors equipped with tablets receive coaching from regional diabetes-nurse networks, reducing travel costs. The France diabetes devices market share for home settings is poised to surpass 30% by 2029 as broadband penetration widens. Pharmacies and ambulatory surgical centers add secondary volumes: pharmacies handle lancets and low-cost glucometers, while day-surgery centers offer sensor insertions and pump starts, creating cross-selling avenues for multinational suppliers focused on the France diabetes devices market.
By Distribution Channel: Digital Commerce Disrupts Traditional Networks
Retail pharmacies booked 42.15% of turnover in 2025, supported by nationwide reach and chronic-disease counseling. Loyalty programs capture repeat strip orders, yet footfall erodes as price-sensitive users migrate online. Pharmacists respond with click-and-collect models, integrating e-storefronts that mirror web discounts and preserve professional interaction in the France diabetes devices market.
Online sales expand 2.90% annually as e-prescription links inside “Mon Espace Santé” auto-populate approved devices. Embecta’s direct-to-consumer portal bundles pen needles and lancets with free next-day delivery, appealing to under-35 users. Mobile checkout reduces friction, and subscription discounts lift reorder predictability. Hospital pharmacies maintain steady demand for implantable sensors and inpatient-use consumables covered by Diagnosis-Related Group (DRG) tariffs. As AID adoption rises, hospital pharmacists take on service contracts, reinforcing institutional influence over the France diabetes devices market.
Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
Urban hubs anchor innovation. Paris, Lyon, and Marseille house half of France’s certified diabetes centers, offering early access to Libre 3, Dexcom G7, and hybrid loops. Data uploaded to “Mon Espace Santé” from these cities informs national policy dashboards that benchmark regional A1c outcomes. The France diabetes devices market size for Île-de-France alone exceeded USD 0.29 billion in 2025 as private insurers co-pay advanced devices. Grenoble and Toulouse leverage microelectronics clusters to attract sensor fabs, turning the Auvergne-Rhône-Alpes region into a med-tech export base and expanding local supplier ecosystems.
Rural departments confront the “medical wasteland” effect, with fewer diabetologists per capita. Teleconsultation volume grew six-fold between 2022 and 2024, bridging these gaps. CGM shipments to rural Occitanie climbed 19% year-on-year in 2024 after Dexcom ONE reimbursement, narrowing access disparities. Pharmacies act as community hubs where nurses insert sensors and teach AID basics, supporting device literacy and retention inside the France diabetes devices market.
Overseas territories reveal unique dynamics. French Guiana’s Parikweneh population registers significantly higher diabetes prevalence linked to dietary transitions. Tailored Creole-language training videos embedded in LibreView platforms improve engagement. Transport delays once hindered sensor delivery, but drone pilots funded under France 2030 now ferry CGM packs to Amazonian clinics, expanding the France diabetes devices market perimeter. Réunion and Martinique adopt similar logistics, fueling steady double-digit sensor growth off a small base.
Competitive Landscape
The France diabetes devices market blends global titans and agile local entrants. Abbott, Dexcom, and Medtronic lead unit sales, jointly controlling about 60% of 2025 revenue. Medtronic’s August 2024 data-sharing pact with Abbott joins Libre sensors to MiniMed pumps, unifying patient dashboards and clinician portals. Dexcom differentiates via 10-day G7 sensors that warm-up in 30 minutes and auto-pair to smartphones, while Abbott counters with 1-hour warm-up Libre 3 at lower list price, sustaining competitive tension that benefits payers.
Domestic innovators capitalize on France 2030 grants. Grenoble-based Sensorion develops silicon-nitride membranes extending sensor life to 21 days, targeting CE mark by 2026. Paris start-up GlucoSurf integrates haptic alerts for visually impaired users, piloting devices under PECAN fast-track before nationwide roll-out. These firms often license patents to majors, gaining channel access while injecting diversity into the France diabetes devices market.
Strategic manufacturing investments amplify local presence. Novo Nordisk expanded a Penfill cartridge plant in Chartres in 2024 to serve European demand. Embecta outsources cannula molding to a Dijon-based contract manufacturer that recently installed EU-MDR-compliant clean rooms, cutting lead times for European deliveries. Competitive differentiation shifts from hardware alone to service layers: remote coaching, A1c predictive analytics, and seamless “Mon Espace Santé” integration. GLP-1 receptor agonists reshape device usage, but CGM enhances titration efficacy; a 2024 study showed A1c declines of 0.5 percentage points when GLP-1 therapy was paired with CGM. Manufacturers therefore position sensors as medication-agnostic companions, sustaining relevance inside the France diabetes devices market.
France Diabetes Devices Industry Leaders
-
Dexcom
-
Abbott
-
Roche
-
Novo Nordisk
-
Medtronic
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- April 2025: Glucotrack joined the FORGETDIABETES consortium to co-develop a bionic pancreas.
- January 2025: Glooko received French reimbursement for remote gestational-diabetes monitoring, expanding digital-health coverage.
- November 2023: Novo Nordisk announced a French plant expansion to meet rising European insulin-device demand.
- September 2023: Dexcom ONE real-time CGM became available nationwide, extending access to 500,000 additional users.
France Diabetes Devices Market Report Scope
More user-friendly and unobtrusive devices are available, from improved insulin pumps to continuous glucose monitors (CGM) and blood glucose meters. The France diabetes device market comprises component management devices and monitoring devices. The report offers the value (in USD) and volume (in units) for the above segments.
By Device Type
| Monitoring Devices | Self-Monitoring Blood Glucose Devices | Glucometers (smart/basic) |
| Test Strips | ||
| Lancets | ||
| Continuous Glucose Monitoring | Sensors | |
| Transmitters & Receivers | ||
| Durables (Transmitters, Re-useable Parts) | ||
| Management Devices | Insulin Delivery Devices | Insulin Pumps |
| Insulin Pump Resorvoir | ||
| Infusion Sets | ||
| Insulin Pens | ||
| Insulin Catridges | ||
By End User
| Hospitals & Clinics |
| Home-care Settings |
| Diabetes Specialty Centres |
| Ambulatory Surgical Centres |
| Pharmacies & Retail Outlets |
By Distribution Channel
| Hospital Pharmacies |
| Retail Pharmacies |
| Online Sales |
| By Device Type | Monitoring Devices | Self-Monitoring Blood Glucose Devices | Glucometers (smart/basic) |
| Test Strips | |||
| Lancets | |||
| Continuous Glucose Monitoring | Sensors | ||
| Transmitters & Receivers | |||
| Durables (Transmitters, Re-useable Parts) | |||
| Management Devices | Insulin Delivery Devices | Insulin Pumps | |
| Insulin Pump Resorvoir | |||
| Infusion Sets | |||
| Insulin Pens | |||
| Insulin Catridges | |||
| By End User | Hospitals & Clinics | ||
| Home-care Settings | |||
| Diabetes Specialty Centres | |||
| Ambulatory Surgical Centres | |||
| Pharmacies & Retail Outlets | |||
| By Distribution Channel | Hospital Pharmacies | ||
| Retail Pharmacies | |||
| Online Sales | |||
Key Questions Answered in the Report
How big is the France Diabetes Devices Market?
The France Diabetes Devices Market size is expected to reach USD 1.39 billion in 2025 and grow at a CAGR of 6.58% to reach USD 1.91 billion by 2030.
How do CEPS price caps affect manufacturers?
CEPS negotiates strict price ceilings based on clinical benefit, compressing margins and pushing companies to add service layers or subscription models to preserve value.
Who are the key players in France Diabetes Devices Market?
Dexcom, Abbott, Roche, Novo Nordisk and Medtronic are the major companies operating in the France Diabetes Devices Market.
Which device type leads the France diabetes devices market?
Monitoring devices, mainly CGM systems, lead with 57.13% market share in 2025 due to nationwide reimbursement and clinician preference for continuous data.
Page last updated on:
